Editorial Material
Hematology
John C. Wood
Summary: This study presents a 10-year follow-up of thalassemia patients with invasively documented pulmonary hypertension, revealing that pulmonary arterial hypertension (PAH) is highly lethal even with sub systemic pressures. The study also highlights the importance of echocardiography in predicting survival based on changes in predicted pulmonary artery pressure.
Article
Pediatrics
Chinmay Chetan, Pradeep Suryawanshi, Suprabha Patnaik, Naharmal B. Soni, Chandra Rath, Prince Pareek, Bhvya Gupta, Reema Garegrat, Arjun Verma, Yogen Singh
Summary: This study compared the efficacy of oral sildenafil and intravenous sildenafil in treating mild to moderate pulmonary hypertension in newborns, finding both forms equally effective in reducing PAP, with intravenous use associated with a higher complication rate.
Review
Chemistry, Multidisciplinary
Raul Edison Luna Lazo, Mariana Mengarda, Susana Leao Almeida, Aline Caldonazo, Joel Toribio Espinoza, Fabio Seigi Murakami
Summary: This review discusses the use of oral sildenafil as a treatment for pulmonary arterial hypertension (PAH) and the development of nano and microparticles for pulmonary drug delivery. The review identifies different colloidal formulations and strategies for targeting the drug to the lungs. It emphasizes the need for future preclinical studies in large animals before clinical trials can be conducted.
JOURNAL OF CONTROLLED RELEASE
(2022)
Article
Respiratory System
Yi Tang, Siyuan Tan, Minqi Li, Yijin Tang, Xiaoping Xu, Qinghai Zhang, Qinghua Fu, Mingxiang Tang, Jin He, Yi Zhang, Zhaofen Zheng, Jianqiang Peng, Tengteng Zhu, Wenlin Xie
Summary: Dapagliflozin reduces right ventricular systolic pressure and pulmonary vascular remodeling in a rat model of pulmonary arterial hypertension. However, combination therapy with dapagliflozin and sildenafil was not more effective than monotherapy with sildenafil in pulmonary arterial hypertension rats.
BMC PULMONARY MEDICINE
(2022)
Article
Pediatrics
Alberto Toso, Oscar Aranguiz, Carlos Cespedes, Orieta Navarrete, Cherie Hernandez, Carlos P. Vio, Matias Luco, Paola Casanello, Javier Kattan
Summary: This study evaluated the effects of antenatal sildenafil and ABH on lung development in a CDH rat model. The results showed that the combined treatment improved lung volume, pulmonary vascular development, and NO synthesis, while preventing smooth muscle cell hyperproliferation. This study highlights the importance of Arginase inhibition as a therapeutic target and the role of prenatal treatment in improving lung development in CDH.
PEDIATRIC RESEARCH
(2022)
Article
Pediatrics
Anna Migdal, Anna Sadel-Wieczorek, Edyta Ryciak, Alicja Mirecka-Rola, Grazyna Brzezinska-Rajszys, Malgorzata Zuk
Summary: This study demonstrated that pulmonary arterial hypertension significantly worsens the prognosis of children with bronchopulmonary dysplasia, but treatment with pulmonary vasodilators shows good efficacy in improving the condition of these patients. Most patients showed improvements in various assessed factors during treatment, with no observed significant side effects.
Article
Engineering, Chemical
Raul Edison Luna Lazo, Bruna de Paula Oliveira, Alexandre de Fatima Cobre, Luana Mota Ferreira, Karina Bettega Felipe, Paulo Renato de Oliveira, Fabio Seigi Murakami
Summary: This study successfully developed SDF-loaded porous micro particles for pulmonary administration, which exhibited high encapsulation efficiency and sustained release, and showed noncytotoxicity at the cellular level.
Article
Biotechnology & Applied Microbiology
Shiho Yoshida, Alexander M. Kreger, George K. Gittes
Summary: We propose that intra-amniotic sildenafil administration is an effective prenatal therapy for CDH-induced pulmonary hypertension. Intra-amniotic sildenafil treatment attenuated peripheral vascular muscularization, enhanced pulmonary blood flow, and improved lung architecture in CDH fetuses. Early intervention with intra-amniotic sildenafil treatment may be preferable to accelerate lung development and improve prognosis in CDH cases.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2023)
Article
Cell Biology
Aleksandra Judina, Marili Niglas, Vladislav Leonov, Nicholas S. Kirkby, Ivan Diakonov, Peter T. Wright, Lan Zhao, Jane A. Mitchell, Julia Gorelik
Summary: This study investigates the synergy between treprostinil and isoprenaline in RV and LV cardiomyocytes in PH patients. It reveals that PH RV cardiomyocytes exhibit maladaptive remodelling, reduced contractility, and impaired response to treprostinil and isoprenaline combination treatment.
Article
Pediatrics
Kacie Dillon, Vineet Lamba, Ranjit R. Philip, Mark F. Weems, Ajay J. Talati
Summary: This study aimed to assess the efficacy of sildenafil in infants with bronchopulmonary dysplasia (BPD)-associated pulmonary hypertension (PH). The study found that sildenafil treatment led to improvement in PH as evaluated by transthoracic echocardiography (TTE), and infants showed improvement in their respiratory severity score (RSS) and FiO2 after prolonged therapy. However, TTE improvements did not correlate with clinical improvements.
Article
Pharmacology & Pharmacy
Xinmei Li, Te Li
Summary: OPLS-DA combined with S-plot is a feasible method for analyzing clinical examination data in patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD). Interventional closure is the preferred treatment option, and postoperative combination of bosentan and sildenafil is more effective than bosentan alone. Early treatment is recommended to prevent recurrence.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Chunhua Fu, Yuanqing Lu, Mason A. Williams, Mark L. Brantly, Corey E. Ventetuolo, Laurence M. Morel, Borna Mehrad, Edward W. Scott, Andrew J. Bryant
Summary: The study investigated the impact of myeloid cell proliferation induced by emergency myelopoiesis on the development of pulmonary hypertension, as well as the therapeutic effect of PD-L1 in preventing pulmonary vascular remodeling. The results showed that PD-L1 could be a viable therapeutic target in pulmonary hypertension by acting through a signaling axis involving myeloid-derived suppressor cells.
BRITISH JOURNAL OF PHARMACOLOGY
(2021)
Article
Biology
Sunil Jit R. J. Logantha, Tomoko T. Yamanushi, Mais Absi, Ian P. Temple, Hideaki Kabuto, Eiichiro Hirakawa, Gillian Quigley, X. Zhang, Alison M. Gurney, George Hart, Henggui Zhang, Halina Dobrzynski, Mark R. Boyett, Joseph Yanni
Summary: Patients with pulmonary arterial hypertension (PAH) exhibit sinus node dysfunction, which is characterized by a decrease in heart rate and arrhythmias. In a rat model of PAH, there were changes in ion channels, Ca2+-handling genes, and fibrosis genes in the sinus node, providing an explanation for the dysfunction.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
(2023)
Article
Cardiac & Cardiovascular Systems
Ze Ming Goh, Nithin Balasubramanian, Samer Alabed, Krit Dwivedi, Yousef Shahin, Alexander M. K. Rothman, Pankaj Garg, Allan Lawrie, David Capener, A. A. Roger Thompson, Faisal Alandejani, Jim M. Wild, Christopher S. Johns, Robert A. Lewis, Rebecca Gosling, Michael Sharkey, Robin Condliffe, David G. Kiely, Andrew J. Swift
Summary: This study investigated the prognostic value of patterns of right ventricular adaptation in patients with pulmonary arterial hypertension (PAH) using cardiac magnetic resonance imaging. The results showed that patients in different volume/mass groups had different survival outcomes, with those in the high-volume-low-mass group having a higher risk of treatment failure.
Article
Pharmacology & Pharmacy
Linli Sun, Chunxia Wang, Yulu Zhou, Wei Sun, Chunjiang Wang
Summary: Different doses of sildenafil can significantly improve persistent pulmonary hypertension of the newborn (PPHN), with 1.5 mg/kg showing better clinical efficacy in reducing pulmonary artery systolic pressure, increasing oxygen partial pressure, and reducing carbon dioxide partial pressure.
FRONTIERS IN PHARMACOLOGY
(2021)